Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity and other serious metabolic diseases

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Novo Nordisk, a leading leading global healthcare company, recently announced the acquisition of Inversago Pharma, a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.

Inversago presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

CryoStasis closes $8 million seed financing to develop next generation sub-zero unfrozen biopreservation for organ transplantation and cell/gene therapy products
Next

FluidAI's artificial intelligence-powered post-surgical monitor, Stream™ Platform, launches globally